From GlobeNewswire: 2025-03-11 07:30:00

Bioventus Inc. (Nasdaq: BVS) reported accelerated fourth-quarter sales growth of 13.5%, with a gross margin expansion of 310 bps. Cash from operations increased by 86.3% to $19.3 million. Full-year 2024 revenue reached $573.3 million, a growth of 11.9%. The company provided full-year 2025 financial guidance anticipating continued revenue growth and operating margin expansion.

The company’s Adjusted EBITDA from continuing operations was $28.3 million, a 28.3% increase from the prior year, driven by strong revenue growth and gross margin expansion. Non-GAAP earnings per share from continuing operations was $0.15, compared to $0.07 in the prior year. Revenue growth was fueled by double-digit growth in Pain Treatments and Surgical Solutions.

Bioventus delivered five consecutive quarters of double-digit revenue growth in Pain Treatments and Surgical Solutions, leading to a 28.3% increase in Adjusted EBITDA in the fourth quarter. The company divested the Advanced Rehabilitation Business, receiving $24.7 million. Bioventus strengthened its balance sheet by reducing long-term debt by $48.3 million in the fourth quarter.

For full-year 2025, Bioventus expects net sales of $560 million to $570 million, reflecting organic growth of approximately 6.1% to 8.0%. Adjusted EBITDA is projected to be $112 million to $116 million, with Non-GAAP EPS of $0.64 to $0.68, reflecting an increase of 30.6% to 38.8%. The company does not provide U.S. GAAP financial measures on a forward-looking basis due to uncertainties related to certain expenses and items.



Read more at GlobeNewswire:: Bioventus Announces Fourth Quarter and Full Year 2024